

## Angiotensin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Wayne Alexander<sup>1</sup>, Kenneth E. Bernstein<sup>1</sup>, Kevin J. Catt<sup>2</sup>, Marc de Gasparo<sup>3</sup>, Khuraijam Dhanachandra Singh<sup>4</sup>, Satoru Eguchi<sup>5</sup>, Emanuel Escher<sup>6</sup>, Theodore L. Goodfriend<sup>7</sup>, Mastgugu Horiuchi<sup>8</sup>, László Hunyady<sup>9</sup>, Ahsan Husain<sup>10</sup>, Tadashi Inagami<sup>11</sup>, Sadashiva Karnik<sup>4</sup>, Jacqueline Kemp<sup>4</sup>, Walter G. Thomas<sup>12</sup>, Pieter B. M. W. M. Timmermans<sup>13</sup>, Kalyan Tirupula<sup>4</sup>, Hamiyet Unal<sup>4</sup>, Thomas Unger<sup>14</sup> and Patrick Vanderheyden<sup>15</sup>

1. Emory University, USA
2. National Institutes of Health, USA
3. Novartis Institutes for Biomedical Research, Switzerland
4. Cleveland Clinic Lerner Research Institute, USA
5. Temple University, USA
6. Universite de Sherbrooke, Canada
7. Veterans Administration Hospital Wisconsin, USA
8. Ehime University, Japan
9. Semmelweis University, Hungary
10. University of Alabama at Birmingham, USA
11. Vanderbilt University, USA
12. University of Queensland, Australia
13. Tularik, USA
14. Christian-Albrechts-Universität zu Kiel, Germany
15. Vrije Universiteit Brussel, Belgium

### Abstract

The actions of [angiotensin II](#) (Ang II) are mediated by AT<sub>1</sub> and AT<sub>2</sub> receptors (**nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors [61, 152]**), which have around 30% sequence similarity. The decapeptide [angiotensin I](#), the octapeptide [angiotensin II](#) and the heptapeptide [angiotensin III](#) are endogenous ligands. [losartan](#), [candesartan](#), [telmisartan](#), etc. are clinically used AT<sub>1</sub> receptor blockers.

### Contents

This is a citation summary for Angiotensin receptors in the [Guide to Pharmacology database \(GtoPdb\)](#). It exists bioRxiv preprint doi: <https://doi.org/10.1101/2019.04.15.306907>; this version posted April 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

[GtoPdb](#) is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those

parts.

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

## Database links

### Angiotensin receptors

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=6>

### Introduction to Angiotensin receptors

<http://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=6>

#### Receptors

##### AT<sub>1</sub> receptor

<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34>

##### AT<sub>2</sub> receptor

<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=35>

## References

1. (1988) Bombesin-like peptides in health and disease. Proceedings of an international symposium. October 13-16, 1987, Rome, Italy. A tribute to Vittorio Erspamer, M.D. *Ann. N. Y. Acad. Sci.* **547**: 1-541 [PMID:3071214]
2. AbdAlla S, Lothar H, el Massiery A and Quitterer U. (2001) Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. *Nat. Med.* **7**: 1003-9 [PMID:11533702]
3. AbdAlla S, Lothar H and Quitterer U. (2000) AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. *Nature* **407**: 94-8 [PMID:10993080]
4. Agelis G, Resvani A, Durdagi S, Spyridaki K, Tůmová T, Slaninová J, Giannopoulos P, Vlahakos D, Liapakis G and Mavromoustakos T *et al.*. (2012) The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butyylimidazole derivatives. *Eur J Med Chem* **55**: 358-74 [PMID:22889560]
5. Agelis G, Resvani A, Koukoulitsa C, Tůmová T, Slaninová J, Kalavrizioti D, Spyridaki K, Afantitis A, Melagraki G and Siafaka A *et al.*. (2013) Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. *Eur J Med Chem* **62**: 352-70 [PMID:23376252]
6. Ahn S, Shenoy SK, Wei H and Lefkowitz RJ. (2004) Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. *J. Biol. Chem.* **279**: 35518-25 [PMID:15205453]
7. Aiyar N, Griffin E, Shu A, Heys R, Bergsma DJ, Weinstock J and Edwards R. (1993) Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor. *J. Recept. Res.* **13**: 849-61 [PMID:8463997]
8. Akishita M, Horiuchi M, Yamada H, Zhang L, Shirakami G, Tamura K, Ouchi Y and Dzau VJ. (2000) Inflammation influences vascular remodeling through AT2 receptor expression and signaling. *Physiol. Genomics* **2**: 13-20 [PMID:11015577]
9. Akishita M, Iwai M, Wu L, Zhang L, Ouchi Y, Dzau VJ and Horiuchi M. (2000) Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. *Circulation* **102**: 1684-9 [PMID:11015348]
10. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ and Connolly LM *et al.*. (2001) Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. *J. Biol. Chem.* **276**: 48623-6 [PMID:11707427]

11. Albiston AL, Mustafa T, McDowall SG, Mendelsohn FA, Lee J and Chai SY. (2003) AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement. *Trends Endocrinol. Metab.* **14**: 72-7 [PMID:12591177]
12. Alfakih K, Maqbool A, Sivananthan M, Walters K, Bainbridge G, Ridgway J, Balmforth AJ and Hall AS. (2004) Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension. *Hypertension* **43**: 1189-94 [PMID:15123577]
13. Allen AM, Moeller I, Jenkins TA, Zhuo J, Aldred GP, Chai SY and Mendelsohn FA. (1998) Angiotensin receptors in the nervous system. *Brain Res. Bull.* **47**: 17-28 [PMID:9766385]
14. Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, Pocchiari F, Felder RA, Eisner GM and Jose PA. (1998) Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. *J. Clin. Invest.* **102**: 493-8 [PMID:9691085]
15. Ayadi Kabadou I, Soualmiaa H, Jemaa R, Feki M, Kallel A, Souheil O, Haj Taieb S, Sanhaji H and Kaabachi N. (2012) Lack of association between C3123A polymorphism of the angiotensin II type 2 receptor gene and hypertension in Tunisian population. *Tunis Med* **90**: 619-24 [PMID:22987376]
16. Baiardi G, Macova M, Armando I, Ando H, Tyurmin D and Saavedra JM. (2005) Estrogen upregulates renal angiotensin II AT1 and AT2 receptors in the rat. *Regul. Pept.* **124**: 7-17 [PMID:15544836]
17. Baker KM, Chernin MI, Wixson SK and Aceto JF. (1990) Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. *Am. J. Physiol.* **259**: H324-32 [PMID:2143633]
18. Baleanu-Gogonea C and Karnik S. (2006) Model of the whole rat AT1 receptor and the ligand-binding site. *J Mol Model* **12**: 325-37 [PMID:16404618]
19. Barber MN, Sampey DB and Widdop RE. (1999) AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. *Hypertension* **34**: 1112-6 [PMID:10567191]
20. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR and Danser AH. (2004) Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. *Circulation* **109**: 2296-301 [PMID:15117835]
21. Bergsma DJ, Ellis C, Kumar C, Nuthulaganti P, Kersten H, Elshourbagy N, Griffin E, Stadel JM and Aiyar N. (1992) Cloning and characterization of a human angiotensin II type 1 receptor. *Biochem. Biophys. Res. Commun.* **183**: 989-95 [PMID:1567413]
22. Berk BC and Corson MA. (1997) Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. *Circ. Res.* **80**: 607-16 [PMID:9130441]
23. Bhatnagar A, Unal H, Jagannathan R, Kaveti S, Duan ZH, Yong S, VasANJI A, Kinter M, Desnoyer R and Karnik SS. (2013) Interaction of G-protein  $\beta\gamma$  complex with chromatin modulates GPCR-dependent gene regulation. *PLoS ONE* **8**: e52689 [PMID:23326349]
24. Bienvenu T, Poirier K, Van Esch H, Hamel B, Moraine C, Fryns JP, Ropers HH, Beldjord C, Yntema HG and Chelly J. (2003) Rare polymorphic variants of the AGTR2 gene in boys with non-specific mental retardation. *J. Med. Genet.* **40**: 357-9 [PMID:12746399]
25. Bonnardeaux A, Davies E, Jeunemaitre X, Féry I, Charru A, Clauser E, Tired L, Cambien F, Corvol P and Soubrier F. (1994) Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. *Hypertension* **24**: 63-9 [PMID:8021009]
26. Booz GW and Baker KM. (1996) Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. *Hypertension* **28**: 635-40 [PMID:8843890]
27. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG and Widdop RE. (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. *Clin. Sci.* **121**: 297-303 [PMID:21542804]
28. Bottari SP, Taylor V, King IN, Bogdal Y, Whitebread S and de Gasparo M. (1991) Angiotensin II AT2 receptors do not interact with guanine nucleotide binding proteins. *Eur. J. Pharmacol.* **207**: 157-63 [PMID:1908781]
29. Brechler V, Jones PW, Levens NR, de Gasparo M and Bottari SP. (1993) Agonistic and antagonistic properties of angiotensin analogs at the AT2 receptor in PC12W cells. *Regul. Pept.* **44**: 207-13

[PMID:8385791]

30. Brede M, Hadamek K, Meinel L, Wiesmann F, Peters J, Engelhardt S, Simm A, Haase A, Lohse MJ and Hein L. (2001) Vascular hypertrophy and increased P70S6 kinase in mice lacking the angiotensin II AT(2) receptor. *Circulation* **104**: 2602-7 [PMID:11714657]
31. Brogelli L, Parenti A and Ledda F. (2002) Inhibition of vascular smooth muscle cell growth by angiotensin type 2 receptor stimulation for in vitro organ culture model. *J. Cardiovasc. Pharmacol.* **39**: 739-45 [PMID:11973418]
32. Buisson B, Laflamme L, Bottari SP, de Gasparo M, Gallo-Payet N and Payet MD. (1995) A G protein is involved in the angiotensin AT2 receptor inhibition of the T-type calcium current in non-differentiated NG108-15 cells. *J. Biol. Chem.* **270**: 1670-4 [PMID:7829501]
33. Bullock GR, Steyaert I, Bilbe G, Carey RM, Kips J, De Paepe B, Pauwels R, Praet M, Siragy HM and de Gasparo M. (2001) Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. *Histochem. Cell Biol.* **115**: 117-24 [PMID:11444146]
34. Bumpus FM, Catt KJ, Chiu AT, DeGasparo M, Goodfriend T, Husain A, Peach MJ, Taylor Jr DG and Timmermans PB. (1991) Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. *Hypertension* **17**: 720-1 [PMID:2022414]
35. Burns KD and Li N. (2003) The role of angiotensin II-stimulated renal tubular transport in hypertension. *Curr. Hypertens. Rep.* **5**: 165-71 [PMID:12642017]
36. Cappelli A, Pericot Mohr GI G, Gallelli A, Rizzo M, Anzini M, Vomero S, Mennuni L, Ferrari F, Makovec F and Menziani MC *et al.*. (2004) Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure. *J. Med. Chem.* **47**: 2574-86 [PMID:15115399]
37. Carey RM, Wang ZQ and Siragy HM. (2000) Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. *Hypertension* **35**: 155-63 [PMID:10642292]
38. Catt KJ, Mendelsohn FA, Millan MA and Aguilera G. (1984) The role of angiotensin II receptors in vascular regulation. *J. Cardiovasc. Pharmacol.* **6 Suppl 4**: S575-86 [PMID:6083400]
39. Catt KJ, Sandberg K and Balla T. (1993) Angiotensin II receptor and signal transduction mechanisms. *In Cellular and molecular biology of the renin-angiotensin system* Edited by Raizada MK, Phillips MI, Summers C: CRC Press: 307-356 [ISBN: 0849346223]
40. Chaki S and Inagami T. (1992) A newly found angiotensin II receptor subtype mediates cyclic GMP formation in differentiated Neuro-2A cells. *Eur. J. Pharmacol.* **225**: 355-6 [PMID:1323479]
41. Chakrabarty A, Blacklock A, Svojanovsky S and Smith PG. (2008) Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. *Endocrinology* **149**: 3452-60 [PMID:18388195]
42. Chang RS and Lotti VJ. (1990) Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. *Mol. Pharmacol.* **37**: 347-51 [PMID:2314387]
43. Chansel D, Vandermeersch S, Pham P and Ardaillou R. (1993) Characterization of [3H]losartan receptors in isolated rat glomeruli. *Eur. J. Pharmacol.* **247**: 193-8 [PMID:8282008]
44. Chaves FJ, Corella D, Sorli JV, Marin-Garcia P, Guillen M and Redon J. (2004) Polymorphisms of the renin-angiotensin system influence height in normotensive women in a Spanish population. *J. Clin. Endocrinol. Metab.* **89**: 2301-5 [PMID:15126556]
45. Chen D, Bassi JK, Walther T, Thomas WG and Allen AM. (2010) Expression of angiotensin type 1A receptors in C1 neurons restores the sympathoexcitation to angiotensin in the rostral ventrolateral medulla of angiotensin type 1A knockout mice. *Hypertension* **56**: 143-50 [PMID:20458002]
46. Chen J, Guo L, Peiffer DA, Zhou L, Chan OT, Bibikova M, Wickham-Garcia E, Lu SH, Zhan Q and Wang-Rodriguez J *et al.*. (2008) Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues. *Int. J. Cancer* **122**: 2249-54 [PMID:18241037]
47. Chen TB, Lotti VJ and Chang RS. (1992) Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand. *Mol. Pharmacol.* **42**: 1077-82 [PMID:1480133]

48. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR and Johnson AL *et al.* (1989) Identification of angiotensin II receptor subtypes. *Biochem. Biophys. Res. Commun.* **165**: 196-203 [PMID:2590220]
49. Chiu AT, McCall DE and Roscoe WA. (1992) [125I]EXP985: a highly potent and specific nonpeptide radioligand antagonist for the AT<sub>1</sub> angiotensin receptor. *Biochem. Biophys. Res. Commun.* **188**: 1030-9 [PMID:1445340]
50. Chow LH, Tao PL, Chen JC, Liao RM, Chang EP and Huang EY. (2013) A possible correlation between oxytocin-induced and angiotensin IV-induced anti-hyperalgesia at the spinal level in rats. *Peptides* **39**: 21-8 [PMID:23142109]
51. Christensen GL, Kelstrup CD, Lyngsø C, Sarwar U, Bøgebo R, Sheikh SP, Gammeltoft S, Olsen JV and Hansen JL. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. *Mol. Cell Proteomics* **9**: 1540-53 [PMID:20363803]
52. Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP and Wood J. (1993) Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT<sub>1</sub>-receptor subtype. *Br. J. Pharmacol.* **110**: 761-71 [PMID:8242249]
53. Cui T, Nakagami H, Iwai M, Takeda Y, Shiuchi T, Daviet L, Nahmias C and Horiuchi M. (2001) Pivotal role of tyrosine phosphatase SHP-1 in AT<sub>2</sub> receptor-mediated apoptosis in rat foetal vascular smooth muscle cell. *Cardiovasc. Res.* **49**: 863-871 [PMID:11230986]
54. Cullinane AB, Leung PS, Ortego J, Coca-Prados M and Harvey BJ. (2002) Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium. *Br J Ophthalmol* **86**: 676-83 [PMID:12034692]
55. Curnow KM, Pascoe L, Davies E, White PC, Corvol P and Clauser E. (1995) Alternatively spliced human type 1 angiotensin II receptor mRNAs are translated at different efficiencies and encode two receptor isoforms. *Mol. Endocrinol.* **9**: 1250-62 [PMID:7491117]
56. Curnow KM, Pascoe L and White PC. (1992) Genetic analysis of the human type-1 angiotensin II receptor. *Mol. Endocrinol.* **6**: 1113-8 [PMID:1508224]
57. da Silva OG, Rossignoli Pde S, Carrillo-Sepúlveda MA, Barreto-Chaves ML and Chies AB. (2011) Involvement of the AT<sub>1</sub> receptor in the venoconstriction induced by angiotensin II in both the inferior vena cava and femoral vein. *Peptides* **32**: 112-7 [PMID:20955746]
58. Davies E, Bonnardeaux A, Lathrop GM, Corvol P, Clauser E and Soubrier F. (1994) Angiotensin II (type-1) receptor locus: CA repeat polymorphism and genetic mapping. *Hum. Mol. Genet.* **3**: 838 [PMID:8081376]
59. Davisson RL, Oliverio MI, Coffman TM and Sigmund CD. (2000) Divergent functions of angiotensin II receptor isoforms in the brain. *J. Clin. Invest.* **106**: 103-6 [PMID:10880053]
60. de Boer RA, Pinto YM, Suurmeijer AJ, Pokharel S, Scholtens E, Humler M, Saavedra JM, Boomsma F, van Gilst WH and van Veldhuisen DJ. (2003) Increased expression of cardiac angiotensin II type 1 (AT<sub>1</sub>) receptors decreases myocardial microvessel density after experimental myocardial infarction. *Cardiovasc. Res.* **57**: 434-42 [PMID:12566116]
61. de Gasparo M, Catt KJ, Inagami T, Wright JW and Unger T. (2000) International union of pharmacology. XXIII. The angiotensin II receptors. *Pharmacol. Rev.* **52**: 415-72 [PMID:10977869]
62. de Gasparo M, Husain A, Alexander W, Catt KJ, Chiu AT, Drew M, Goodfriend T, Harding JW, Inagami T and Timmermans PB. (1995) Proposed update of angiotensin receptor nomenclature. *Hypertension* **25**: 924-7 [PMID:7737728]
63. de Gasparo M and Siragy HM. (1999) The AT<sub>2</sub> receptor: fact, fancy and fantasy. *Regul. Pept.* **81**: 11-24 [PMID:10395404]
64. de Gasparo M and Whitebread S. (1995) Binding of valsartan to mammalian angiotensin AT<sub>1</sub> receptors. *Regul. Pept.* **59**: 303-11 [PMID:8577935]
65. de Gasparo M, Whitebread S, Bottari SP and Levens NR. (1994) Heterogeneity of angiotensin receptor subtypes. In *Medicinal Chemistry of the Renin-Angiotensin System*. Edited by Timmermanns PBMWM, Wexler RR: Elsevier: 269-294 [ISBN: 0444820531]
66. de Gasparo MBottari. (1995) Characteristics of angiotensin II receptors and their role in cell and organ

- physiology. *In Hypertension: Pathophysiology, Diagnosis, and Management 1*: Edited by Laragh JH, Brenner BM: Raven Press Ltd.: 1695-1720 [ISBN: 0781701570]
67. De Paolis P, Porcellini A, Savoia C, Lombardi A, Gigante B, Frati G, Rubattu S, Musumeci B and Volpe M. (2002) Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. *J. Hypertens.* **20**: 693-9 [PMID:11910305]
  68. Demaegdt H, Lukaszuk A, De Buyser E, De Backer JP, Szemenyei E, Tóth G, Chakravarthy S, Panicker M, Michotte Y and Tourwé D *et al.*. (2009) Selective labeling of IRAP by the tritiated AT(4) receptor ligand [3H]Angiotensin IV and its stable analog [3H]AL-11. *Mol. Cell. Endocrinol.* **311**: 77-86 [PMID:19643163]
  69. Dimitropoulou C, White RE, Fuchs L, Zhang H, Catravas JD and Carrier GO. (2001) Angiotensin II relaxes microvessels via the AT(2) receptor and Ca(2+)-activated K(+) (BK(Ca)) channels. *Hypertension* **37**: 301-7 [PMID:11230289]
  70. Dimmeler S, Rippmann V, Weiland U, Haendeler J and Zeiher AM. (1997) Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. *Circ. Res.* **81**: 970-6 [PMID:9400377]
  71. Doan TN, Ali MS and Bernstein KE. (2001) Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling. *J. Biol. Chem.* **276**: 20954-8 [PMID:11319216]
  72. Dudley DT, Hubbell SE and Summerfelt RM. (1991) Characterization of angiotensin II (AT2) binding sites in R3T3 cells. *Mol. Pharmacol.* **40**: 360-7 [PMID:1896025]
  73. Dudley DT, Panek RL, Major TC, Lu GH, Bruns RF, Klinkefus BA, Hodges JC and Weishaar RE. (1990) Subclasses of angiotensin II binding sites and their functional significance. *Mol. Pharmacol.* **38**: 370-7 [PMID:2402226]
  74. Dudley DT and Summerfelt RM. (1993) Regulated expression of angiotensin II (AT2) binding sites in R3T3 cells. *Regul. Pept.* **44**: 199-206 [PMID:8469774]
  75. Dzau VJ and Horiuchi M. (1996) Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis. *Eur. Heart J.* **17**: 978-80 [PMID:8809509]
  76. Dzau VJ, Mukoyama M and Pratt RE. (1994) Molecular biology of angiotensin receptors: target for drug research? *J Hypertens Suppl* **12**: S1-5 [PMID:7965260]
  77. Díez J, Laviades C, Orbe J, Zalba G, López B, González A, Mayor G, Páramo JA and Beloqui O. (2003) The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. *J. Hypertens.* **21**: 2085-92 [PMID:14597852]
  78. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, Keenan RM, Ruffolo RR and Weinstock J. (1992) Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. *J. Pharmacol. Exp. Ther.* **260**: 175-81 [PMID:1309870]
  79. Eguchi S, Dempsey PJ, Frank GD, Motley ED and Inagami T. (2001) Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. *J. Biol. Chem.* **276**: 7957-62 [PMID:11116149]
  80. Elton TS, Stephan CC, Taylor GR, Kimball MG, Martin MM, Durand JN and Oparil S. (1992) Isolation of two distinct type I angiotensin II receptor genes. *Biochem. Biophys. Res. Commun.* **184**: 1067-73 [PMID:1575725]
  81. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP and Ruiz-Ortega M *et al.*. (2009) Angiotensin-(1-7) and the G protein-coupled receptor MAS are key players in renal inflammation. *PLoS ONE* **4**: e5406 [PMID:19404405]
  82. Esteban V, Lorenzo O, Rupérez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido J and Ruiz-Ortega M. (2004) Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. *J. Am. Soc. Nephrol.* **15**: 1514-29 [PMID:15153562]
  83. Esteban V, Ruperez M, Vita JR, López ES, Mezzano S, Plaza JJ, Egido J and Ruiz-Ortega M. (2003) Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. *Kidney Int. Suppl.* S33-8 [PMID:12969125]
  84. Eto H, Biro S, Miyata M, Kaieda H, Obata H, Kihara T, Orihara K and Tei C. (2003) Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodeling after vascular injury.

- Cardiovasc. Res.* **59**: 200-11 [PMID:12829191]
85. Feng YH, Noda K, Saad Y, Liu XP, Husain A and Karnik SS. (1995) The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism. *J. Biol. Chem.* **270**: 12846-50 [PMID:7759541]
  86. Feng YH, Saad Y and Karnik SS. (2000) Reversible inactivation of AT(2) angiotensin II receptor from cysteine-disulfide bond exchange. *FEBS Lett.* **484**: 133-8 [PMID:11068047]
  87. Feng YH, Sun Y and Douglas JG. (2002) Gbeta gamma -independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1. *Proc. Natl. Acad. Sci. U.S.A.* **99**: 12049-54 [PMID:12221292]
  88. Ferri C, Desideri G, Baldoncini R, Bellini C, Valenti M, Santucci A and De Mattia G. (1999) Angiotensin II increases the release of endothelin-1 from human cultured endothelial cells but does not regulate its circulating levels. *Clin. Sci.* **96**: 261-70 [PMID:10029562]
  89. Fierens F, Vanderheyden PM, De Backer JP and Vauquelin G. (1999) Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. *Eur. J. Pharmacol.* **367**: 413-22 [PMID:10079018]
  90. Fierens FL, Vanderheyden PM, De Backer JP and Vauquelin G. (1999) Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. *Eur. J. Pharmacol.* **372**: 199-206 [PMID:10395100]
  91. Fillion D, Cabana J, Guillemette G, Leduc R, Lavigne P and Escher E. (2013) Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode. *J. Biol. Chem.* **288**: 8187-97 [PMID:23386604]
  92. Finnerup NB and Baastrop C. (2014) Angiotensin II: from blood pressure to pain control *Lancet* **383**: 1613-4 [PMID:24507378]
  93. Fischer TA, Singh K, O'Hara DS, Kaye DM and Kelly RA. (1998) Role of AT<sub>1</sub> and AT<sub>2</sub> receptors in regulation of MAPKs and MKP-1 by Ang II in adult cardiac myocytes. *Am. J. Physiol.* **275**: H906-H916 [PMID:9724295]
  94. Friedman RC, Farh KK, Burge CB and Bartel DP. (2009) Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* **19**: 92-105 [PMID:18955434]
  95. Furuta H, Guo DF and Inagami T. (1992) Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. *Biochem. Biophys. Res. Commun.* **183**: 8-13 [PMID:1543512]
  96. Gallinat S, Yu M, Dorst A, Unger T and Herdegen T. (1998) Sciatic nerve transection evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in adult rat dorsal root ganglia and sciatic nerves. *Brain Res. Mol. Brain Res.* **57**: 111-22 [PMID:9630555]
  97. Gao L and Zucker IH. (2011) AT2 receptor signaling and sympathetic regulation. *Curr Opin Pharmacol* **11**: 124-30 [PMID:21159555]
  98. Gasc JM, Shanmugam S, Sibony M and Corvol P. (1994) Tissue-specific expression of type 1 angiotensin II receptor subtypes. An *in situ* hybridization study. *Hypertension* **24**: 531-537 [PMID:7960011]
  99. Geerts H, de Brabander M and Nuydens R. (1991) Nanovid microscopy. *Nature* **351**: 765-6 [PMID:1712078]
  100. Gohlke P, Pees C and Unger T. (1998) AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. *Hypertension* **31**: 349-55 [PMID:9453327]
  101. Gold S, Haran I, Attias J, Shapira I and Shahar A. (1989) Biochemical and cardiovascular measures in subjects with noise-induced hearing loss. *J Occup Med* **31**: 933-7 [PMID:2809800]
  102. Goodfriend TL, Elliott ME and Catt KJ. (1996) Angiotensin receptors and their antagonists. *N. Engl. J. Med.* **334**: 1649-54 [PMID:8628362]
  103. Gribouval O, Gonzales M, Neuhaus T, Aziza J, Bieth E, Laurent N, Bouton JM, Feuillet F, Makni S and Ben Amar H *et al.*. (2005) Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. *Nat. Genet.* **37**: 964-8 [PMID:16116425]
  104. Griendling KK, Lassègue B and Alexander RW. (1996) Angiotensin receptors and their therapeutic implications. *Annu. Rev. Pharmacol. Toxicol.* **36**: 281-306 [PMID:8725391]
  105. Griendling KK and Ushio-Fukai M. (2000) Reactive oxygen species as mediators of angiotensin II

- signaling. *Regul. Pept.* **91**: 21-7 [PMID:10967199]
106. Griendling KK, Ushiofukai M, Lassegue B and Alexander RW. (1997) Angiotensin II signaling in vascular smooth muscle - new concepts. *Hypertension* **29**: 366-373 [PMID:9039129]
  107. Haithcock D, Jiao H, Cui XL, Hopfer U and Douglas JG. (1999) Renal proximal tubular AT<sub>2</sub> receptor: signaling and transport. *J Am Soc Nephrol.* **10**: S69-S74 [PMID:9892143]
  108. Hallberg M. (2009) Targeting the insulin-regulated aminopeptidase/AT4 receptor for cognitive disorders. *Drug News Perspect.* **22**: 133-9 [PMID:19440555]
  109. Hancock AA, Surber BW, Rotert G, Thomas S, Tasker AS, Sorensen BK, Vodenlich AD, Oppenorth TJ, Kerkman DJ and DeBernardis JF. (1994) [3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. *Eur. J. Pharmacol.* **267**: 49-54 [PMID:8206129]
  110. Handa RK, Krebs LT, Harding JW and Handa SE. (1998) Angiotensin IV AT4-receptor system in the rat kidney. *Am. J. Physiol.* **274**: F290-9 [PMID:9486224]
  111. Hanley MR, Cheung WT, Hawkins P, Poyner D, Benton HP, Blair L, Jackson TR and Goedert M. (1990) The mas oncogene as a neural peptide receptor: expression, regulation and mechanism of action. *Ciba Found. Symp.* **150**: 23-38; discussion 38-46 [PMID:2197067]
  112. Hansen JL, Servant G, Baranski TJ, Fujita T, Iiri T and Sheikh SP. (2000) Functional reconstitution of the angiotensin II type 2 receptor and G(i) activation. *Circ. Res.* **87**: 753-9 [PMID:11055978]
  113. Harada K, Sugaya T, Murakami K, Yazaki Y and Komuro I. (1999) Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. *Circulation* **100**: 2093-9 [PMID:10562266]
  114. Harding JW, Cook VI, Miller-Wing AV, Hanesworth JM, Sardinia MF, Hall KL, Stobb JW, Swanson GN, Coleman JK and Wright JW *et al.*. (1992) Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampus. *Brain Res.* **583**: 340-3 [PMID:1504842]
  115. Hein L, Barsh GS, Pratt RE, Dzau VJ and Kobilka BK. (1995) Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. *Nature* **377**: 744-7 [PMID:7477266]
  116. Hein L, Dzau VJ and Barsh GS. (1995) Linkage mapping of the angiotensin A<sub>2</sub> receptor gene (Agtr2) to the mouse X chromosome. *Genomics* **30**: 369-371 [PMID:8586443]
  117. Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK and Dzau VJ. (1997) Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. *Proc. Natl. Acad. Sci. U.S.A.* **94**: 6391-6 [PMID:9177228]
  118. Hernandez Schulman I, Zhou MS and Raji L. (2007) Cross-talk between angiotensin II receptor types 1 and 2: potential role in vascular remodeling in humans. *Hypertension* **49**: 270-1 [PMID:17159080]
  119. Herradon G, Ezquerro L, Nguyen T, Vogt TF, Bronson R, Silos-Santiago I and Deuel TF. (2004) Pleiotrophin is an important regulator of the renin-angiotensin system in mouse aorta. *Biochem. Biophys. Res. Commun.* **324**: 1041-7 [PMID:15485659]
  120. Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley Jr AW, Izumo S and Markham BE. (1997) Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. *Proc. Natl. Acad. Sci. U.S.A.* **94**: 7543-8 [PMID:9207128]
  121. Hilditch A, Hunt AA, Travers A, Polley J, Drew GM, Middlemiss D, Judd DB, Ross BC and Robertson MJ. (1995) Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist. *J. Pharmacol. Exp. Ther.* **272**: 750-7 [PMID:7853190]
  122. Hoffmann S, Krause T, van Geel PP, Willenbrock R, Pagel I, Pinto YM, Buikema H, van Gilst WH, Lindschau C and Paul M *et al.*. (2001) Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy. *J. Mol. Med.* **79**: 601-8 [PMID:11692158]
  123. Hoffmann S, Podlich D, Hähnel B, Kriz W and Gretz N. (2004) Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. *J. Am. Soc. Nephrol.* **15**: 1475-87 [PMID:15153558]
  124. Hollon TR, Bek MJ, Lachowicz JE, Ariano MA, Mezey E, Ramachandran R, Wersinger SR, Soares-da-Silva P, Liu ZF and Grinberg A *et al.*. (2002) Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. *J. Neurosci.* **22**: 10801-10 [PMID:12486173]



125. Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ and Thomas WG. (2002) Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. *Mol. Pharmacol.* **61**: 768-77 [PMID:11901215]
126. Holycross BJ, Peach MJ and Owens GK. (1993) Angiotensin II stimulates increased protein synthesis, not increased DNA synthesis, in intact rat aortic segments, in vitro. *J. Vasc. Res.* **30**: 80-6 [PMID:8504199]
127. Horiuchi M, Akishita M and Dzau VJ. (1999) Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. *Hypertension* **33**: 613-21 [PMID:10024316]
128. Horiuchi M, Hayashida W, Kambe T, Yamada T and Dzau VJ. (1997) Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. *J. Biol. Chem.* **272**: 19022-6 [PMID:9228085]
129. Horiuchi M, Lehtonen JY and Daviet L. (1999) Signaling Mechanism of the AT2 Angiotensin II Receptor: Crosstalk between AT1 and AT2 Receptors in Cell Growth. *Trends Endocrinol. Metab.* **10**: 391-396 [PMID:10542395]
130. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA and Inagami T. (2002) Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. *Circulation* **106**: 2244-2249 [PMID:12390955]
131. Ichihara S, Senbonmatsu T, Price Jr E, Ichiki T, Gaffney FA and Inagami T. (2001) Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. *Circulation* **104**: 346-51 [PMID:11457756]
132. Ichiki T and Inagami T. (1995) Expression, genomic organization, and transcription of the mouse angiotensin II type 2 receptor gene. *Circ. Res.* **76**: 693-700 [PMID:7728985]
133. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL and Inagami T. (1995) Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. *Nature* **377**: 748-50 [PMID:7477267]
134. Inagami T, Iwai N, Sasaki K, Guo DF, Furuta H, Yamano Y, Bardhan S, Chaki S, Makito N and Badr K. (1993) Angiotensin II receptors: cloning and regulation. *Arzneimittelforschung* **43**: 226-8 [PMID:8498969]
135. Inagami T, Iwai N, Sasaki K, Yamano Y, Bardhan S, Chaki S, Guo DF, Furuta H, Ohyama K and Kambayashi Y *et al.*. (1994) Cloning, expression and regulation of angiotensin II receptors. *Eur. Heart J.* **15 Suppl D**: 104-7 [PMID:7713098]
136. Inokuchi S, Kimura K, Sugaya T, Inokuchi K, Murakami K and Sakai T. (2001) Hyperplastic vascular smooth muscle cells of the intrarenal arteries in angiotensin II type 1a receptor null mutant mice. *Kidney Int.* **60**: 722-31 [PMID:11473655]
137. Ishida M, Marrero MB, Schieffer B, Ishida T, Bernstein KE and Berk BC. (1995) Angiotensin II activates pp60c-src in vascular smooth muscle cells. *Circ. Res.* **77**: 1053-9 [PMID:7586216]
138. Itoh S, Ding B, Shishido T, Lerner-Marmarosh N, Wang N, Maekawa N, Berk BC, Takeishi Y, Yan C and Blaxall BC *et al.*. (2006) Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. *Circulation* **113**: 1787-98 [PMID:16585392]
139. Iwai N and Inagami T. (1992) Identification of two subtypes in the rat type I angiotensin II receptor. *FEBS Lett.* **298**: 257-60 [PMID:1544458]
140. Iwai N, Yamano Y, Chaki S, Konishi F, Bardhan S, Tibbetts C, Sasaki K, Hasegawa M, Matsuda Y and Inagami T. (1991) Rat angiotensin II receptor: cDNA sequence and regulation of the gene expression. *Biochem. Biophys. Res. Commun.* **177**: 299-304 [PMID:2043116]
141. Jaffré F, Bonnin P, Callebort J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC and Launay JM *et al.*. (2009) Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. *Circ. Res.* **104**: 113-23 [PMID:19023134]
142. Jagannathan R, Kaveti S, Desnoyer RW, Willard B, Kinter M and Karnik SS. (2010) AT1 receptor induced alterations in histone H2A reveal novel insights into GPCR control of chromatin remodeling. *PLoS ONE* **5**: e12552 [PMID:20838438]
143. Jaiswal N, Tallant EA, Jaiswal RK, Diz DI and Ferrario CM. (1993) Differential regulation of prostaglandin

- synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. *J. Pharmacol. Exp. Ther.* **265**: 664-73 [PMID:8496814]
144. Jankowski V, Vanholder R, van der Giet M, Tölle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E and Tran TN *et al.* (2007) Mass-spectrometric identification of a novel angiotensin peptide in human plasma. *Arterioscler. Thromb. Vasc. Biol.* **27**: 297-302 [PMID:17138938]
  145. Jin W, Liu Y, Sheng HH, Jin L, Shen YY, Hua Q, Lu L, Yu JD and Huang W. (2003) Single nucleotide polymorphisms in promoter of angiotensin II type 1 receptor gene associated with essential hypertension and coronary heart disease in Chinese population. *Acta Pharmacol. Sin.* **24**: 1083-8 [PMID:14627489]
  146. Jin XQ, Fukuda N, Su JZ, Lai YM, Suzuki R, Tahira Y, Takagi H, Ikeda Y, Kanmatsuse K and Miyazaki H. (2002) Angiotensin II type 2 receptor gene transfer downregulates angiotensin II type 1a receptor in vascular smooth muscle cells. *Hypertension* **39**: 1021-7 [PMID:12019286]
  147. Jones A, Dhamrait SS, Payne JR, Hawe E, Li P, Toor IS, Luong L, Wootton PT, Miller GJ and Humphries SE *et al.* (2003) Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. *Hypertension* **42**: 500-6 [PMID:12925562]
  148. Kakar SS, Sellers JC, Devor DC, Musgrove LC and Neill JD. (1992) Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. *Biochem. Biophys. Res. Commun.* **183**: 1090-6 [PMID:1567388]
  149. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T and Inagami T. (1993) Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. *J. Biol. Chem.* **268**: 24543-6 [PMID:8227011]
  150. Kang J, Richards EM, Posner P and Sumners C. (1995) Modulation of the delayed rectifier K<sup>+</sup> current in neurons by an angiotensin II type 2 receptor fragment. *Am. J. Physiol.* **268**: C278-82 [PMID:7840157]
  151. Kanome T, Watanabe T, Nishio K, Takahashi K, Hongo S and Miyazaki A. (2008) Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II Type 1 receptor in human monocyte-macrophages. *Hypertens. Res.* **31**: 1801-10 [PMID:18971559]
  152. Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PM and Thomas WG. (2015) International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. *Pharmacol. Rev.* **67**: 754-819 [PMID:26315714]
  153. Katada J and Majima M. (2002) AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. *Br. J. Pharmacol.* **136**: 484-91 [PMID:12055126]
  154. Kemp BA, Bell JF, Rottkamp DM, Howell NL, Shao W, Navar LG, Padia SH and Carey RM. (2012) Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. *Hypertension* **60**: 387-95 [PMID:22689743]
  155. Kim JM, Heo HS, Ha YM, Ye BH, Lee EK, Choi YJ, Yu BP and Chung HY. (2012) Mechanism of Ang II involvement in activation of NF- $\kappa$ B through phosphorylation of p65 during aging. *Age (Dordr)* **34**: 11-25 [PMID:21318332]
  156. Kim NH, Ahn Y, Oh SK, Cho JK, Park HW, Kim YS, Hong MH, Nam KI, Park WJ and Jeong MH *et al.* (2005) Altered patterns of gene expression in response to chronic atrial fibrillation. *Int Heart J* **46**: 383-95 [PMID:16043935]
  157. Kobashi G, Hata A, Ohta K, Yamada H, Kato EH, Minakami H, Fujimoto S and Kondo K. (2004) A1166C variant of angiotensin II type 1 receptor gene is associated with severe hypertension in pregnancy independently of T235 variant of angiotensinogen gene. *J. Hum. Genet.* **49**: 182-6 [PMID:15042429]
  158. Koerten HK, de Bruijn JD and Daems WT. (1990) The formation of asbestos bodies by mouse peritoneal macrophages. An in vitro study. *Am. J. Pathol.* **137**: 121-34 [PMID:2372038]
  159. Koike G, Horiuchi M, Yamada T, Szpirer C, Jacob HJ and Dzau VJ. (1994) Human type 2 angiotensin II receptor gene cloned, mapped to the x chromosome, and its mRNA is expressed in the human lung. *Biochem. Biophys. Res. Commun.* **203**: 1842-1850 [PMID:7945336]
  160. Koike H, Sada T and Mizuno M. (2001) In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. *J Hypertens Suppl* **19**: S3-14 [PMID:11451212]
  161. Konishi H, Kuroda S, Inada Y and Fujisawa Y. (1994) Novel subtype of human angiotensin II type 1

- receptor: cDNA cloning and expression. *Biochem. Biophys. Res. Commun.* **199**: 467-74 [PMID:8135787]
162. Kotani K, Sakane N and Taniguchi N. (2013) Association between angiotensin II Type 2 receptor gene A/C3123 polymorphism and high-density lipoprotein cholesterol with hypertension in asymptomatic women. *Med Princ Pract* **22**: 65-9 [PMID:22869520]
163. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y and Iba O *et al.*. (2003) Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. *Hypertension* **41**: 99-107 [PMID:12511537]
164. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A and Lind L. (2002) Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. *J. Hypertens.* **20**: 657-63 [PMID:11910301]
165. Kuroda S, Konishi H, Okishio M and Fujisawa Y. (1994) Novel subtype of human angiotensin II type 1 receptor: analysis of signal transduction mechanism in transfected Chinese hamster ovary cells. *Biochem. Biophys. Res. Commun.* **199**: 475-481 [PMID:8135788]
166. Kurosaka M, Suzuki T, Hosono K, Kamata Y, Fukamizu A, Kitasato H, Fujita Y and Majima M. (2009) Reduced angiogenesis and delay in wound healing in angiotensin II type 1a receptor-deficient mice. *Biomed. Pharmacother.* **63**: 627-34 [PMID:19464844]
167. Kwon TH, Nielsen J, Kim YH, Knepper MA, Frokiaer J and Nielsen S. (2003) Regulation of sodium transporters in the thick ascending limb of rat kidney: response to angiotensin II. *Am. J. Physiol. Renal Physiol.* **285**: F152-F165 [PMID:12657563]
168. Langford K, Frenzel K, Martin BM and Bernstein KE. (1992) The genomic organization of the rat AT1 angiotensin receptor. *Biochem. Biophys. Res. Commun.* **183**: 1025-32 [PMID:1533121]
169. Lawnicka H, Ptasinska-Wnuk D, Mucha S, Kunert-Radek J, Pawlikowski M and Stepien H. (2012) The involvement of angiotensin type 1 and type 2 receptors in estrogen-induced cell proliferation and vascular endothelial growth factor expression in the rat anterior pituitary. *ScientificWorldJournal* **2012**: 358102 [PMID:22645419]
170. Lazartigues E, Dunlay SM, Loihl AK, Sinnayah P, Lang JA, Espelund JJ, Sigmund CD and Davisson RL. (2002) Brain-selective overexpression of angiotensin (AT1) receptors causes enhanced cardiovascular sensitivity in transgenic mice. *Circ. Res.* **90**: 617-24 [PMID:11909827]
171. Lazartigues E, Lawrence AJ, Lamb FS and Davisson RL. (2004) Renovascular hypertension in mice with brain-selective overexpression of AT1a receptors is buffered by increased nitric oxide production in the periphery. *Circ. Res.* **95**: 523-31 [PMID:15284190]
172. Lazartigues E, Sinnayah P, Augoyard G, Gharib C, Johnson AK and Davisson RL. (2008) Enhanced water and salt intake in transgenic mice with brain-restricted overexpression of angiotensin (AT1) receptors. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **295**: R1539-45 [PMID:18753266]
173. Le MT, Vanderheyden PM, Szaszák M, Hunyady L and Vauquelin G. (2002) Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N- and C-terminal residues of angiotensin II during AT1 receptor activation. *J. Biol. Chem.* **277**: 23107-10 [PMID:12006574]
174. Lee HB, Yu MR, Yang Y, Jiang Z and Ha H. (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. *J. Am. Soc. Nephrol.* **14**: S241-5 [PMID:12874439]
175. Leung KH, Smith RD, Timmermans BM and Chiu AT. (1991) Regional distribution of the two subtypes of angiotensin II receptor in rat brain using selective nonpeptide antagonists. *Neurosci. Lett.* **123**: 95-98 [PMID:2062460]
176. Lewis BP, Burge CB and Bartel DP. (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **120**: 15-20 [PMID:15652477]
177. Li H, Qi Y, Li C, Braseth LN, Gao Y, Shabashvili AE, Katovich MJ and Sumners C. (2009) Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. *Mol. Cancer Ther.* **8**: 3255-65 [PMID:19996275]
178. Li H, Weatherford ET, Davis DR, Keen HL, Grobe JL, Daugherty A, Cassis LA, Allen AM and Sigmund CD. (2011) Renal proximal tubule angiotensin AT1A receptors regulate blood pressure. *Am. J. Physiol. Regul.*

- Integr. Comp. Physiol.* **301**: R1067-77 [PMID:21753145]
179. Li XC, Shao Y and Zhuo JL. (2009) AT1a receptor knockout in mice impairs urine concentration by reducing basal vasopressin levels and its receptor signaling proteins in the inner medulla. *Kidney Int.* **76**: 169-77 [PMID:19387470]
  180. Lokuta AJ, Cooper C, Gaa ST, Wang HE and Rogers TB. (1994) Angiotensin II stimulates the release of phospholipid-derived second messenger through multiple receptor subtypes in heart cells. *J. Biol. Chem.* **269**: 4832-4838 [PMID:8106454]
  181. Loyens E, De Bundel D, Demaegdt H, Chai SY, Vanderheyden P, Michotte Y, Gard P and Smolders I. (2013) Antidepressant-like effects of oxytocin in mice are dependent on the presence of insulin-regulated aminopeptidase. *Int. J. Neuropsychopharmacol.* **16**: 1153-63 [PMID:23177092]
  182. Loyens E, Schallier A, Chai SY, De Bundel D, Vanderheyden P, Michotte Y and Smolders I. (2011) Deletion of insulin-regulated aminopeptidase in mice decreases susceptibility to pentylenetetrazol-induced generalized seizures. *Seizure* **20**: 602-5 [PMID:21612947]
  183. Luchtefeld M, Bandlow N, Tietge UJ, Grote K, Pfeilschifter J, Kaszkin M, Beck S, Drexler H and Schieffer B. (2007) Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation. *Atherosclerosis* **194**: 62-70 [PMID:17069818]
  184. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J and Unger T. (1998) The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. *J. Exp. Med.* **188**: 661-70 [PMID:9705948]
  185. Luttrell LM and Gesty-Palmer D. (2010) Beyond desensitization: physiological relevance of arrestin-dependent signaling. *Pharmacol. Rev.* **62**: 305-30 [PMID:20427692]
  186. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ and Harrison DG. (2010) Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. *Hypertension* **55**: 500-7 [PMID:20038749]
  187. Maillard MP, Rossat J, Brunner HR and Burnier M. (2000) Tasosartan, enoltasartan, and angiotensin II receptor blockade: the confounding role of protein binding. *J. Pharmacol. Exp. Ther.* **295**: 649-54 [PMID:11046101]
  188. Mangrum AJ, Gomez RA and Norwood VF. (2002) Effects of AT(1A) receptor deletion on blood pressure and sodium excretion during altered dietary salt intake. *Am. J. Physiol. Renal Physiol.* **283**: F447-53 [PMID:12167595]
  189. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P and Bernstein KE. (1995) Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. *Nature* **375**: 247-50 [PMID:7746328]
  190. Marrero MB, Schieffer B, Paxton WG, Schieffer E and Bernstein KE. (1995) Electroporation of pp60c-src antibodies inhibits the angiotensin II activation of phospholipase C-gamma 1 in rat aortic smooth muscle cells. *J. Biol. Chem.* **270**: 15734-8 [PMID:7541047]
  191. Martin MM, Willardson BM, Burton GF, White CR, McLaughlin JN, Bray SM, Ogilvie JW Jr and Elton TS. (2001) Human angiotensin II type 1 receptor isoforms encoded by messenger RNA splice variants are functionally distinct. *Mol. Endocrinol.* **15**: 281-293 [PMID:11158334]
  192. Matsubara H. (1998) Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. *Circ. Res.* **83**: 1182-91 [PMID:9851935]
  193. Matsusaka T and Ichikawa I. (1997) Biological functions of angiotensin and its receptors. *Annu. Rev. Physiol.* **59**: 395-412 [PMID:9074770]
  194. Maul B, von Bohlen und Halbach O, Becker A, Sterner-Kock A, Voigt JP, Siems WE, Grecksch G and Walther T. (2008) Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice. *J. Mol. Med.* **86**: 563-71 [PMID:18335189]
  195. Mauzy CA, Hwang O, Egloff AM, Wu LH and Chung FZ. (1992) Cloning, expression, and characterization of a gene encoding the human angiotensin II type 1A receptor. *Biochem. Biophys. Res. Commun.* **186**: 277-84 [PMID:1378723]
  196. McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, Kuffa P, Kohrt D, Mak TW and Nuñez G *et al.* (2007) CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive

- inflammatory signaling in nonimmune cells. *Proc. Natl. Acad. Sci. U.S.A.* **104**: 139-44 [PMID:17101977]
197. McClellan KJ and Markham A. (1998) Telmisartan. *Drugs* **56**: 1039-44; discussion 1045-6 [PMID:9878991]
198. Menk M, Graw JA, von Haefen C, Siffringer M, Schwaiberger D, Unger T, Steckelings U and Spies CD. (2015) Stimulation of the Angiotensin II AT2 Receptor is Anti-inflammatory in Human Lipopolysaccharide-Activated Monocytic Cells. *Inflammation* **38**: 1690-9 [PMID:25758542]
199. Mertens B, Vanderheyden P, Michotte Y and Sarre S. (2010) Direct angiotensin II type 2 receptor stimulation decreases dopamine synthesis in the rat striatum. *Neuropharmacology* **58**: 1038-44 [PMID:20097214]
200. Michel MC, Foster C, Brunner HR and Liu L. (2013) A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. *Pharmacol. Rev.* **65**: 809-48 [PMID:23487168]
201. Mifune M, Sasamura H, Shimizu-Hirota R, Miyazaki H and Saruta T. (2000) Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. *Hypertension* **36**: 845-50 [PMID:11082154]
202. Mii S, Ware JA, Mallette SA and Kent KC. (1994) Effect of angiotensin II on human vascular smooth muscle cell growth. *J. Surg. Res.* **57**: 174-8 [PMID:8041134]
203. Millatt LJ, Abdel-Rahman EM and Siragy HM. (1999) Angiotensin II and nitric oxide: a question of balance. *Regul. Pept.* **81**: 1-10 [PMID:10395403]
204. Miura S, Feng YH, Husain A and Karnik SS. (1999) Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. *J. Biol. Chem.* **274**: 7103-10 [PMID:10066768]
205. Miura S and Karnik SS. (2000) Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. *EMBO J.* **19**: 4026-35 [PMID:10921883]
206. Miura S, Karnik SS and Saku K. (2011) Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. *J Renin Angiotensin Aldosterone Syst* **12**: 1-7 [PMID:20603272]
207. Moeller I, Lew RA, Mendelsohn FA, Smith AI, Brennan ME, Tetaz TJ and Chai SY. (1997) The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT4 receptor in the brain. *J. Neurochem.* **68**: 2530-7 [PMID:9166749]
208. Morphy R and Rankovic Z. (2005) Designed multiple ligands. An emerging drug discovery paradigm. *J. Med. Chem.* **48**: 6523-43 [PMID:16220969]
209. Mueller CF, Berger A, Zimmer S, Tiyerili V and Nickenig G. (2009) The heterogenous nuclear riboprotein S1-1 regulates AT1 receptor gene expression via transcriptional and posttranscriptional mechanisms. *Arch. Biochem. Biophys.* **488**: 76-82 [PMID:19508861]
210. Mukohda M, Yamawaki H, Okada M and Hara Y. (2010) Methylglyoxal augments angiotensin II-induced contraction in rat isolated carotid artery. *J. Pharmacol. Sci.* **114**: 390-8 [PMID:21076237]
211. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE and Dzau VJ. (1993) Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. *J. Biol. Chem.* **268**: 24539-42 [PMID:8227010]
212. Murphy TJ, Alexander RW, Griendling KK, Runge MS and Bernstein KE. (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. *Nature* **351**: 233-6 [PMID:2041570]
213. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE and Dzau VJ. (1995) The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. *Proc. Natl. Acad. Sci. U.S.A.* **92**: 10663-7 [PMID:7479861]
214. Nakanishi M, Harada M, Kishimoto I, Kuwahara K, Kawakami R, Nakagawa Y, Yasuno S, Usami S, Kinoshita H and Adachi Y *et al.*. (2007) Genetic disruption of angiotensin II type 1a receptor improves long-term survival of mice with chronic severe aortic regurgitation. *Circ. J.* **71**: 1310-6 [PMID:17652901]
215. Namsolleck P, Boato F, Schwengel K, Paulis L, Matho KS, Geurts N, Thöne-Reineke C, Lucht K, Seidel K and Hallberg A *et al.*. (2013) AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. *Neurobiol. Dis.* **51**: 177-91 [PMID:23174180]
216. Natarajan K, Yin G and Berk BC. (2004) Scaffolds direct Src-specific signaling in response to angiotensin II: new roles for Cas and GIT1. *Mol. Pharmacol.* **65**: 822-5 [PMID:15044610]

217. Navar LG, Kobori H and Prieto-Carrasquero M. (2003) Intrarenal angiotensin II and hypertension. *Curr. Hypertens. Rep.* **5**: 135-43 [PMID:12642013]
218. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L and Pirrelli A. (1999) Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. *Hypertension* **33**: 719-25 [PMID:10024335]
219. Nie YY, Da YJ, Zheng H, Yang XX, Jia L, Wen CH, Liang LS, Tian J and Chen ZL. (2012) Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect. *Bioorg. Med. Chem.* **20**: 2747-61 [PMID:22410249]
220. Nishimura H, Yerkes E, Hohenfellner K, Miyazaki Y, Ma J, Hunley TE, Yoshida H, Ichiki T, Threadgill D and Phillips 3rd JA *et al.*. (1999) Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. *Mol. Cell* **3**: 1-10 [PMID:10024874]
221. Noda K, Saad Y and Karnik SS. (1995) Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. *J. Biol. Chem.* **270**: 28511-4 [PMID:7499361]
222. Noda K, Saad Y, Kinoshita A, Boyle TP, Graham RM, Husain A and Karnik SS. (1995) Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. *J. Biol. Chem.* **270**: 2284-9 [PMID:7530721]
223. Northcott CA, Watts S, Chen Y, Morris M, Chen A and Haywood JR. (2010) Adenoviral inhibition of AT1a receptors in the paraventricular nucleus inhibits acute increases in mean arterial blood pressure in the rat. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **299**: R1202-11 [PMID:20702798]
224. Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, Alleaume AM, Di Benedetto M, Boden C and Masson M *et al.*. (2004) Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. *J. Biol. Chem.* **279**: 28989-97 [PMID:15123706]
225. Nouet S and Nahmias C. (2000) Signal transduction from the angiotensin II AT2 receptor. *Trends Endocrinol. Metab.* **11**: 1-6 [PMID:10652498]
226. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y and Shibazaki Y *et al.*. (1997) Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. *Circulation* **96**: 3954-62 [PMID:9403620]
227. Ohlstein EH, Brooks DP, Feuerstein GZ and Ruffolo RR Jr. (1997) Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. *Pharmacology* **55**: 244-251 [PMID:9399334]
228. Ohyama K, Yamano Y, Sano T, Nakagomi Y, Wada M and Inagami T. (2002) Role of the conserved DRY motif on G protein activation of rat angiotensin II receptor type 1A. *Biochem. Biophys. Res. Commun.* **292**: 362-7 [PMID:11906170]
229. Olins GM, Corpus VM, Chen ST, McMahon EG, Palomo MA, McGraw DE, Smits GJ, Null CL, Brown MA and Bittner SE *et al.*. (1993) Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonist. *J. Cardiovasc. Pharmacol.* **22**: 617-25 [PMID:7505365]
230. Oriji GK. (1999) Nitric oxide in cyclosporine A-induced hypertension: endothelin receptors gene expression. *Prostaglandins Leukot. Essent. Fatty Acids* **61**: 41-4 [PMID:10477041]
231. Ott C, Titze SI, Schwarz TK, Kreutz R, Hilgers KF, Schmidt BM, Schlaich MP and Schmieder RE. (2007) High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. *J. Hypertens.* **25**: 1627-32 [PMID:17620959]
232. Padia SH, Kemp BA, Howell NL, Fournie-Zaluski MC, Roques BP and Carey RM. (2008) Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats. *Hypertension* **51**: 460-5 [PMID:18158338]
233. Pang J, Yan C, Natarajan K, Cavet ME, Massett MP, Yin G and Berk BC. (2008) GIT1 mediates HDAC5 activation by angiotensin II in vascular smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* **28**: 892-8 [PMID:18292392]
234. Paradis P, Dali-Youcef N, Paradis FW, Thibault G and Nemer M. (2000) Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. *Proc. Natl. Acad. Sci.*

- U.S.A. **97**: 931-6 [PMID:10639182]
235. Perlman S, Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA and Schwartz TW. (1995) Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor. *J. Biol. Chem.* **270**: 1493-6 [PMID:7829475]
236. Petracco RG, Kong A, Grechukhina O, Krikun G and Taylor HS. (2012) Global gene expression profiling of proliferative phase endometrium reveals distinct functional subdivisions. *Reprod Sci* **19**: 1138-45 [PMID:22623515]
237. Porrello ER, D'Amore A, Curl CL, Allen AM, Harrap SB, Thomas WG and Delbridge LM. (2009) Angiotensin II type 2 receptor antagonizes angiotensin II type 1 receptor-mediated cardiomyocyte autophagy. *Hypertension* **53**: 1032-40 [PMID:19433781]
238. Prescott MF, Webb RL and Reidy MA. (1991) Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. *Am. J. Pathol.* **139**: 1291-6 [PMID:1750504]
239. Putnam K, Batifoulier-Yiannikouris F, Bharadwaj KG, Lewis E, Karounos M, Daugherty A and Cassis LA. (2012) Deficiency of angiotensin type 1a receptors in adipocytes reduces differentiation and promotes hypertrophy of adipocytes in lean mice. *Endocrinology* **153**: 4677-86 [PMID:22919058]
240. Qadri F, Culman J, Veltmar A, Maas K, Rascher W and Unger T. (1993) Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus. *J. Pharmacol. Exp. Ther.* **267**: 567-74 [PMID:8246129]
241. Quitterer U, Fu X, Pohl A, Bayoumy KM, Langer A and AbdAlla S. (2019) Beta-Arrestin1 Prevents Preeclampsia by Downregulation of Mechanosensitive AT1-B2 Receptor Heteromers. *Cell* **176**: 318-333.e19 [PMID:30503206]
242. Rakugi H, Nakata E, Sasaki E and Kagawa T. (2014) Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension. *Clin Ther* **36**: 711-21 [PMID:24742498]
243. Ramchandran R, Takezako T, Saad Y, Stull L, Fink B, Yamada H, Dikalov S, Harrison DG, Moravec C and Karnik SS. (2006) Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response. *Proc. Natl. Acad. Sci. U.S.A.* **103**: 19087-92 [PMID:17148616]
244. Reaux A, Iturrioz X, Vazeux G, Fournie-Zaluski MC, David C, Roques BP, Corvol P and Llorens-Cortes C. (2000) Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. *Biochem. Soc. Trans.* **28**: 435-40 [PMID:10961935]
245. Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T and Unger T. (2003) Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. *FASEB J.* **17**: 2094-6 [PMID:14500552]
246. Renieri A, Pescucci C, Longo I, Ariani F, Mari F and Meloni I. (2005) Non-syndromic X-linked mental retardation: from a molecular to a clinical point of view. *J. Cell. Physiol.* **204**: 8-20 [PMID:15690397]
247. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE and Bhojani MS *et al.*. (2009) AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. *Proc. Natl. Acad. Sci. U.S.A.* **106**: 10284-9 [PMID:19487683]
248. Rice AS, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G and Desem N *et al.*. (2014) EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. *Lancet* **383**: 1637-47 [PMID:24507377]
249. Rivard K, Grandy SA, Douillette A, Paradis P, Nemer M, Allen BG and Fiset C. (2011) Overexpression of type 1 angiotensin II receptors impairs excitation-contraction coupling in the mouse heart. *Am. J. Physiol. Heart Circ. Physiol.* **301**: H2018-27 [PMID:21856918]
250. Ruan X, Oliverio MI, Coffman TM and Arendshorst WJ. (1999) Renal vascular reactivity in mice: AngII-

- induced vasoconstriction in AT1A receptor null mice. *J. Am. Soc. Nephrol.* **10**: 2620-30 [PMID:10589703]
251. Rueckschloss U, Quinn MT, Holtz J and Morawietz H. (2002) Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. *Arterioscler. Thromb. Vasc. Biol.* **22**: 1845-51 [PMID:12426214]
252. Ruiz-Ortega M, Ruperez M, Esteban V and Egido J. (2003) Molecular mechanisms of angiotensin II-induced vascular injury. *Curr. Hypertens. Rep.* **5**: 73-9 [PMID:12530939]
253. Saavedra JM, Armando I, Terrón JA, Falcón-Neri A, Jöhren O, Häuser W and Inagami T. (2001) Increased AT(1) receptors in adrenal gland of AT(2) receptor gene-disrupted mice. *Regul. Pept.* **102**: 41-7 [PMID:11600209]
254. Sadoshima J. (2000) Cytokine actions of angiotensin II. *Circ. Res.* **86**: 1187-9 [PMID:10864905]
255. Sandberg K, Ji H, Clark AJ, Shapira H and Catt KJ. (1992) Cloning and expression of a novel angiotensin II receptor subtype. *J. Biol. Chem.* **267**: 9455-8 [PMID:1374402]
256. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT and Bader M *et al.*. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc. Natl. Acad. Sci. U.S.A.* **100**: 8258-63 [PMID:12829792]
257. Sasaki K, Murohara T, Ikeda H, Sugaya T, Shimada T, Shintani S and Imaizumi T. (2002) Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. *J. Clin. Invest.* **109**: 603-11 [PMID:11877468]
258. Sasamura H, Hein L, Krieger JE, Pratt RE, Kobilka BK and Dzau VJ. (1992) Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. *Biochem. Biophys. Res. Commun.* **185**: 253-9 [PMID:1599461]
259. Satoh K, Ichihara K, Landon EJ, Inagami T and Tang H. (2001) 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors block calcium-dependent tyrosine kinase Pyk2 activation by angiotensin II in vascular endothelial cells. involvement of geranylgeranylation of small G protein Rap1. *J. Biol. Chem.* **276**: 15761-7 [PMID:11278472]
260. Saulière A, Bellot M, Paris H, Denis C, Finana F, Hansen JT, Altié MF, Seguelas MH, Pathak A and Hansen JL *et al.*. (2012) Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. *Nat. Chem. Biol.* **8**: 622-30 [PMID:22634635]
261. Sayeski PP, Ali MS, Hawks K, Frank SJ and Bernstein KE. (1999) The angiotensin II-dependent association of Jak2 and c-Src requires the N-terminus of Jak2 and the SH2 domain of c-Src. *Circ. Res.* **84**: 1332-8 [PMID:10364571]
262. Sayeski PP, Ali MS, Semeniuk DJ, Doan TN and Bernstein KE. (1998) Angiotensin II signal transduction pathways. *Regul. Pept.* **78**: 19-29 [PMID:9879743]
263. Schiffrin EL and Touyz RM. (1998) Vascular biology of endothelin. *J. Cardiovasc. Pharmacol.* **32 Suppl 3**: S2-13 [PMID:9883741]
264. Senbonmatsu T, Saito T, Landon EJ, Watanabe O, Price Jr E, Roberts RL, Imboden H, Fitzgerald TG, Gaffney FA and Inagami T. (2003) A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. *EMBO J.* **22**: 6471-82 [PMID:14657020]
265. Seyedi N, Xu X, Nasjletti A and Hintze TH. (1995) Coronary kinin generation mediates nitric oxide release after angiotensinreceptor stimulation. *Hypertension* **26**: 164-170 [PMID:7607720]
266. Shetty SS and DelGrande D. (2000) Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan. *J. Pharmacol. Exp. Ther.* **294**: 179-86 [PMID:10871310]
267. Silvestre JS, Tamarat R, Senbonmatsu T, Ickhiki T, Ebrahimian T, Iglarz M, Besnard S, Duriez M, Inagami T and Lévy BI. (2002) Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. *Circ. Res.* **90**: 1072-9 [PMID:12039796]
268. Siragy HM and Carey RM. (1997) The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. *J. Clin. Invest.* **100**: 264-9 [PMID:9218502]
269. Siragy HM, de Gasparo M and Carey RM. (2000) Angiotensin type 2 receptor mediates valsartan-induced



- hypotension in conscious rats. *Hypertension* **35**: 1074-7 [PMID:10818067]
270. Siragy HM, El-Kersh MA, De Gasparo M, Webb RL and Carey RM. (2002) Differences in AT<sub>2</sub>-receptor stimulation between AT<sub>1</sub>-receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. *J. Hypertens.* **20**: 1157-63 [PMID:12023686]
  271. Siragy HM, Inagami T, Ichiki T and Carey RM. (1999) Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT<sub>2</sub>) angiotensin receptor. *Proc. Natl. Acad. Sci. U.S.A.* **96**: 6506-10 [PMID:10339618]
  272. Smith GR and Missailidis S. (2004) Cancer, inflammation and the AT<sub>1</sub> and AT<sub>2</sub> receptors. *J Inflamm (Lond)* **1**: 3 [PMID:15813980]
  273. Smith MT, Wyse BD and Edwards SR. (2013) Small molecule angiotensin II type 2 receptor (AT<sub>2</sub>R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. *Pain Med* **14**: 692-705 [PMID:23489258]
  274. Smith RD and Timmermans PB. (1994) Human angiotensin receptor subtypes. *Curr. Opin. Nephrol. Hypertens.* **3**: 112-22 [PMID:7850406]
  275. Smith S and Ramirez VD. (2002) Direct visualization of internalization and intracellular trafficking of dopamine-releasing protein-36aa. *Neuroendocrinology* **75**: 98-112 [PMID:11867938]
  276. Sohn HY, Raff U, Hoffmann A, Gloe T, Heermeier K, Galle J and Pohl U. (2000) Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. *Br. J. Pharmacol.* **131**: 667-72 [PMID:11030714]
  277. Speth RC and Kim KH. (1990) Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine<sup>6</sup> angiotensin II. *Biochem. Biophys. Res. Commun.* **169**: 997-1006 [PMID:2194459]
  278. Stoll M, Steckelings UM, Bottari SP, Paul M, Metzger R and Unger T. (1995) The Angiotensin AT<sub>2</sub>-receptor mediates inhibition of cell proliferation in coronary endothelial cells. *J. Clin. Invest.* **95**: 651-657 [PMID:7860748]
  279. Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, Jungbauer A and Wolzt M. (2008) Angiotensin inhibition stimulates PPAR<sub>γ</sub> and the release of visfatin. *Eur. J. Clin. Invest.* **38**: 820-6 [PMID:19021699]
  280. Stroth U, Blume A, Mielke K and Unger T. (2000) Angiotensin AT<sub>2</sub> receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. *Brain Res. Mol. Brain Res.* **78**: 175-80 [PMID:10891597]
  281. Sugiura N, Hagiwara H and Hirose S. (1992) Molecular cloning of porcine soluble angiotensin-binding protein. *J. Biol. Chem.* **267**: 18067-72 [PMID:1517239]
  282. Sung CP, Arleth AJ, Storer BL and Ohlstein EH. (1994) Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. *J. Pharmacol. Exp. Ther.* **271**: 429-37 [PMID:7965744]
  283. Swindle JD, Santos KL and Speth RC. (2013) Pharmacological characterization of a novel non-AT<sub>1</sub>, non-AT<sub>2</sub> angiotensin binding site identified as neurolysin. *Endocrine* **44**: 525-31 [PMID:23412923]
  284. Takahara M, Shiraiwa T, Shindo M, Arai A, Kusuda Y, Katakami N, Kaneto H, Matsuoka TA and Shimomura I. (2014) Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial. *Hypertens. Res.* **37**: 852-7 [PMID:24739538]
  285. Takayanagi R, Ohnaka K, Sakai Y, Nakao R, Yanase T, Haji M, Inagami T, Furuta H, Gou DF and Nakamuta M *et al.*. (1992) Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor. *Biochem. Biophys. Res. Commun.* **183**: 910-6 [PMID:1550596]
  286. Takezako T, Gogonea C, Saad Y, Noda K and Karnik SS. (2004) "Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists. *J. Biol. Chem.* **279**: 15248-57 [PMID:14754891]
  287. Tamura M, Wanaka Y, Landon EJ and Inagami T. (1999) Intracellular sodium modulates the expression of angiotensin II subtype 2 receptor in PC12W cells. *Hypertension* **33**: 626-32 [PMID:10024318]

288. Tanaka M, Tsuchida S, Imai T, Fujii N, Miyazaki H, Ichiki T, Naruse M and Inagami T. (1999) Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 knockout mice. *Biochem. Biophys. Res. Commun.* **258**: 194-8 [PMID:10222259]
289. Tang SS, Rogg H, Schumacher R and Dzau VJ. (1992) Characterization of nuclear angiotensin-II-binding sites in rat liver and comparison with plasma membrane receptors. *Endocrinology* **131**: 374-80 [PMID:1612017]
290. Thomas WG, Qian H, Chang CS and Karnik S. (2000) Agonist-induced phosphorylation of the angiotensin II (AT(1A)) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. *J. Biol. Chem.* **275**: 2893-900 [PMID:10644757]
291. Timmermans PB. (1999) Pharmacological properties of angiotensin II receptor antagonists. *Can J Cardiol* **15 Suppl F**: 26F-8F [PMID:10579749]
292. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA and Smith RD. (1993) Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol. Rev.* **45**: 205-51 [PMID:8372104]
293. Tissir F, Rivière M, Guo DF, Tsuzuki S, Inagami T, Levan G, Szpirer J and Szpirer C. (1995) Localization of the genes encoding the three rat angiotensin II receptors, Agtr1a, Agtr1b, Agtr2, and the human AGTR2 receptor respectively to rat chromosomes 17q12, 2q24 and Xq34, and the human Xq22. *Cytogenet. Cell Genet.* **71**: 77-80 [PMID:7606933]
294. Tohgo A, Choy EW, Gesty-Palmer D, Pierce KL, Laporte S, Oakley RH, Caron MG, Lefkowitz RJ and Luttrell LM. (2003) The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. *J. Biol. Chem.* **278**: 6258-67 [PMID:12473660]
295. Touyz RM, He G, El Mabrouk M and Schiffrin EL. (2001) p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. *Hypertension* **37**: 574-80 [PMID:11230337]
296. Tsuchida S, Matsusaka T, Chen X, Okubo S, Niimura F, Nishimura H, Fogo A, Utsunomiya H, Inagami T and Ichikawa I. (1998) Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. *J. Clin. Invest.* **101**: 755-60 [PMID:9466969]
297. Tsutsumi K and Saavedra JM. (1991) Differential development of angiotensin II receptor subtypes in the rat brain. *Endocrinology* **128**: 630-2 [PMID:1986946]
298. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R and Nakagawa K *et al.*. (1999) Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. *J. Clin. Invest.* **104**: 925-35 [PMID:10510333]
299. Unal H, Jagannathan R, Bhat MB and Karnik SS. (2010) Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. *J. Biol. Chem.* **285**: 16341-50 [PMID:20299456]
300. Unal H, Jagannathan R, Bhatnagar A, Tirupula K, Desnoyer R and Karnik SS. (2013) Long range effect of mutations on specific conformational changes in the extracellular loop 2 of angiotensin II type 1 receptor. *J. Biol. Chem.* **288**: 540-51 [PMID:23139413]
301. Underwood DJ, Strader CD, Rivero R, Patchett AA, Greenlee W and Prendergast K. (1994) Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. *Chem. Biol.* **1**: 211-21 [PMID:9383393]
302. Unger T. (1999) The angiotensin type 2 receptor: variations on an enigmatic theme. *J. Hypertens.* **17**: 1775-86 [PMID:10703869]
303. van Kesteren CA, van Heugten HA, Lamers JM, Saxena PR, Schalekamp MA and Danser AH. (1997) Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. *J. Mol. Cell. Cardiol.* **29**: 2147-57 [PMID:9281446]
304. Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N and Vauquelin G. (1999) Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. *Br. J. Pharmacol.* **126**: 1057-65 [PMID:10193788]
305. Vanderheyden PM, Verheijen I, Fierens FL, Backer JP and Vauquelin G. (2000) Binding characteristics of

- [(3)H]-irbesartan to human recombinant angiotensin type 1 receptors. *J Renin Angiotensin Aldosterone Syst* **1**: 159-65 [PMID:11967808]
306. Vanderheyden PM, Verheijen I, Fierens FL, DeBacker JP and Vauquelin G. (2000) Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors. *Pharm. Res.* **17**: 1482-8 [PMID:11303957]
307. Vauquelin G, Michotte Y, Smolders I, Sarre S, Ebinger G, Dupont A and Vanderheyden P. (2002) Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. *J Renin Angiotensin Aldosterone Syst* **3**: 195-204 [PMID:12584663]
308. Verdonk K, Durik M, Abd-Alla N, Batenburg WW, van den Bogaerd AJ, van Veghel R, Roks AJ, Danser AH and van Esch JH. (2012) Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. *Hypertension* **60**: 722-9 [PMID:22802221]
309. Verheijen I, Fierens FL, Debacker JP, Vauquelin G and Vanderheyden PM. (2000) Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. *Fundam. Clin. Pharmacol.* **14**: 577-585 [PMID:11206708]
310. Vervoort VS, Beachem MA, Edwards PS, Ladd S, Miller KE, de Mollerat X, Clarkson K, DuPont B, Schwartz CE and Stevenson RE *et al.*. (2002) AGTR2 mutations in X-linked mental retardation. *Science* **296**: 2401-3 [PMID:12089445]
311. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M and Lark MW. (2010) Selectively engaging  $\beta$ -arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. *J. Pharmacol. Exp. Ther.* **335**: 572-9 [PMID:20801892]
312. Vázquez J, Correa de Adjounian MF, Sumners C, González A, Diez-Freire C and Raizada MK. (2005) Selective silencing of angiotensin receptor subtype 1a (AT1aR) by RNA interference. *Hypertension* **45**: 115-9 [PMID:15569855]
313. Wallukat G, Nissen E, Neichel D and Harris J. (2002) Spontaneously beating neonatal rat heart myocyte culture-a model to characterize angiotensin II at(1) receptor autoantibodies in patients with preeclampsia. *In Vitro Cell. Dev. Biol. Anim.* **38**: 376-7 [PMID:12534336]
314. Wang WY, Zee RY and Morris BJ. (1997) Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. *Clin. Genet.* **51**: 31-4 [PMID:9084931]
315. Wangler NJ, Santos KL, Schadock I, Hagen FK, Escher E, Bader M, Speth RC and Karamyan VT. (2012) Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site. *J. Biol. Chem.* **287**: 114-22 [PMID:22039052]
316. Webb ML, Liu EC, Cohen RB, Hedberg A, Bogosian EA, Monshizadegan H, Molloy C, Serafino R, Moreland S and Murphy TJ *et al.*. (1992) Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cells. *Peptides* **13**: 499-508 [PMID:1326103]
317. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM and Lefkowitz RJ. (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. *Proc. Natl. Acad. Sci. U.S.A.* **100**: 10782-7 [PMID:12949261]
318. Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD and Timmermans PB. (1996) Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. *J. Med. Chem.* **39**: 625-56 [PMID:8576904]
319. Whitebread S, Mele M, Kamber B and de Gasparo M. (1989) Preliminary biochemical characterization of two angiotensin II receptor subtypes. *Biochem. Biophys. Res. Commun.* **163**: 284-91 [PMID:2775266]
320. Whitebread SE, Taylor V, Bottari SP, Kamber B and de Gasparo M. (1991) Radioiodinated CGP 42112A: a novel high affinity and highly selective ligand for the characterization of angiotensin AT2 receptors. *Biochem. Biophys. Res. Commun.* **181**: 1365-71 [PMID:1764088]
321. Wiemer G, Schölkens BA, Wagner A, Heitsch H and Linz W. (1993) The possible role of angiotensin II subtype AT2 receptors in endothelial cells and isolated ischemic rat hearts. *J Hypertens Suppl* **11**: S234-5 [PMID:8158361]
322. Wiest SA, Rampersaud A, Zimmerman K and Steinberg MI. (1991) Characterization of distinct angiotensin

- II binding sites in rat adrenal gland and bovine cerebellum using selective nonpeptide antagonists. *J. Cardiovasc. Pharmacol.* **17**: 177-84 [PMID:1709220]
323. Wu L, Iwai M, Li Z, Shiuchi T, Min LJ, Cui TX, Li JM, Okumura M, Nahmias C and Horiuchi M. (2004) Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. *Mol. Endocrinol.* **18**: 666-78 [PMID:14684844]
324. Wu L, Iwai M, Nakagami H, Chen R, Suzuki J, Akishita M, de Gasparo M and Horiuchi M. (2002) Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice. *Arterioscler. Thromb. Vasc. Biol.* **22**: 49-54 [PMID:11788460]
325. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M and Horiuchi M. (2001) Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. *Circulation* **104**: 2716-21 [PMID:11723025]
326. Wu Z, Maric C, Roesch DM, Zheng W, Verbalis JG and Sandberg K. (2003) Estrogen regulates adrenal angiotensin AT1 receptors by modulating AT1 receptor translation. *Endocrinology* **144**: 3251-61 [PMID:12810582]
327. Xia Y, Wen H, Bobst S, Day MC and Kellems RE. (2003) Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. *J. Soc. Gynecol. Investig.* **10**: 82-93 [PMID:12593997]
328. Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Kapke A and Yang XP. (2002) Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. *Hypertension* **40**: 244-50 [PMID:12215461]
329. Yahata Y, Shirakata Y, Tokumaru S, Yang L, Dai X, Tohyama M, Tsuda T, Sayama K, Iwai M and Horiuchi M *et al.*. (2006) A novel function of angiotensin II in skin wound healing. Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation. *J. Biol. Chem.* **281**: 13209-16 [PMID:16543233]
330. Yamada H, Akishita M, Ito M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ and Horiuchi M. (1999) AT2 receptor and vascular smooth muscle cell differentiation in vascular development. *Hypertension* **33**: 1414-9 [PMID:10373225]
331. Yamada T, Akishita M, Pollman MJ, Gibbons GH, Dzau VJ and Horiuchi M. (1998) Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. *Life Sci.* **63**: PL289-95 [PMID:9806232]
332. Yamada T, Horiuchi M and Dzau VJ. (1996) Angiotensin II type 2 receptor mediates programmed cell death. *Proc. Natl. Acad. Sci. U.S.A.* **93**: 156-60 [PMID:8552595]
333. Yamada Y, Yamauchi D, Usui H, Zhao H, Yokoo M, Ohinata K, Iwai M, Horiuchi M and Yoshikawa M. (2008) Hypotensive activity of novokinin, a potent analogue of ovokinin(2-7), is mediated by angiotensin AT(2) receptor and prostaglandin IP receptor. *Peptides* **29**: 412-8 [PMID:18207609]
334. Yan C, Kim D, Aizawa T and Berk BC. (2003) Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. *Arterioscler. Thromb. Vasc. Biol.* **23**: 26-36 [PMID:12524221]
335. Yang R, Smolders I, Vanderheyden P, Demaegdt H, Van Eeckhaut A, Vauquelin G, Lukaszuk A, Tourwé D, Chai SY and Albiston AL *et al.*. (2011) Pressor and renal hemodynamic effects of the novel angiotensin A peptide are angiotensin II type 1A receptor dependent. *Hypertension* **57**: 956-64 [PMID:21464395]
336. Yang R, Walther T, Gembardt F, Smolders I, Vanderheyden P, Albiston AL, Chai SY and Dupont AG. (2010) Renal vasoconstrictor and pressor responses to angiotensin IV in mice are AT1a-receptor mediated. *J. Hypertens.* **28**: 487-94 [PMID:19907343]
337. Yang Z, Bove CM, French BA, Epstein FH, Berr SS, DiMaria JM, Gibson JJ, Carey RM and Kramer CM. (2002) Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. *Circulation* **106**: 106-11 [PMID:12093778]
338. Yasuda N, Akazawa H, Ito K, Shimizu I, Kudo-Sakamoto Y, Yabumoto C, Yano M, Yamamoto R, Ozasa Y and Minamino T *et al.*. (2012) Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice. *Hypertension* **59**: 627-33 [PMID:22291447]

339. Ye MQ and Healy DP. (1992) Characterization of an angiotensin type-1 receptor partial cDNA from rat kidney: evidence for a novel AT1B receptor subtype. *Biochem. Biophys. Res. Commun.* **185**: 204-10 [PMID:1599457]
340. Yerkes E, Nishimura H, Miyazaki Y, Tsuchida S, Brock 3rd JW and Ichikawa I. (1998) Role of angiotensin in the congenital anomalies of the kidney and urinary tract in the mouse and the human. *Kidney Int. Suppl.* **67**: S75-7 [PMID:9736258]
341. Ylisaukko-oja T, Rehnström K, Vanhala R, Tengström C, Lähdetie J and Järvelä I. (2004) Identification of two AGTR2 mutations in male patients with non-syndromic mental retardation. *Hum. Genet.* **114**: 211-3 [PMID:14598163]
342. Yoneda A, Cascio S, Green A, Barton D and Puri P. (2002) Angiotensin II type 2 receptor gene is not responsible for familial vesicoureteral reflux. *J. Urol.* **168**: 1138-41 [PMID:12187255]
343. Yoshida H, Kakuchi J, Guo DF, Furuta H, Iwai N, van der Meer-de Jong R, Inagami T and Ichikawa I. (1992) Analysis of the evolution of angiotensin II type 1 receptor gene in mammals (mouse, rat, bovine and human). *Biochem. Biophys. Res. Commun.* **186**: 1042-9 [PMID:1497638]
344. Yu L, Shao C and Gao L. (2014) Developmental expression patterns for angiotensin receptors in mouse skin and brain. *J Renin Angiotensin Aldosterone Syst* **15**: 139-49 [PMID:23204186]
345. Yue H, Li W, Desnoyer R and Karnik SS. (2010) Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. *Cardiovasc. Res.* **85**: 90-9 [PMID:19696070]
346. Zahradka P, Werner JP, Buhay S, Litchie B, Helwer G and Thomas S. (2002) NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. *J. Mol. Cell. Cardiol.* **34**: 1609-21 [PMID:12505059]
347. Zhang H, Unal H, Desnoyer R, Han GW, Patel N, Katritch V, Karnik SS, Cherezov V and Stevens RC. (2015) Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor. *J. Biol. Chem.* **290**: 29127-39 [PMID:26420482]
348. Zhang H, Unal H, Gati C, Han GW, Liu W, Zatsopin NA, James D, Wang D, Nelson G and Weierstall *Uet al.* (2015) Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. *Cell* **161**: 833-44 [PMID:25913193]
349. Zhang J and Pratt RE. (1996) The AT2 receptor selectively associates with Gialpha2 and Gialpha3 in the rat fetus. *J. Biol. Chem.* **271**: 15026-33 [PMID:8663053]
350. Zhao Y, Biermann T, Luther C, Unger T, Culman J and Gohlke P. (2003) Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells. *J. Neurochem.* **85**: 759-67 [PMID:12694402]
351. Zhou A, Dekker GA, Lumbers ER, Lee SY, Thompson SD, McCowan LM, Roberts CT and SCOPE consortium. (2013) The association of AGTR2 polymorphisms with preeclampsia and uterine artery bilateral notching is modulated by maternal BMI. *Placenta* **34**: 75-81 [PMID:23122839]
352. Zhu L, Carretero OA, Liao TD, Harding P, Li H, Sumners C and Yang XP. (2010) Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. *Hypertension* **56**: 384-90 [PMID:20606103]
353. Zhu M, Natarajan R, Nadler JL, Moore JM, Gelband CH and Sumners C. (2000) Angiotensin II increases neuronal delayed rectifier K(+) current: role of 12-lipoxygenase metabolites of arachidonic acid. *J. Neurophysiol.* **84**: 2494-501 [PMID:11067992]
354. Zhu Z, Zhang SH, Wagner C, Kurtz A, Maeda N, Coffman T and Arendshorst WJ. (1998) Angiotensin AT1B receptor mediates calcium signaling in vascular smooth muscle cells of AT1A receptor-deficient mice. *Hypertension* **31**: 1171-7 [PMID:9576131]
355. Zimpelmann J and Burns KD. (2001) Angiotensin II AT(2) receptors inhibit growth responses in proximal tubule cells. *Am. J. Physiol. Renal Physiol.* **281**: F300-8 [PMID:11457722]